Russia’s cancer vaccine set for approval after promising trial results

Russia’s experimental cancer vaccine has successfully cleared preclinical trials, proving both safe and highly effective, according to Russian state news agency TASS.

Veronika Skvortsova, head of the Federal Medical and Biological Agency (FMBA), announced at the Eastern Economic Forum (EEF) that the vaccine has been in development for several years, with the past three devoted to mandatory preclinical studies.

“The vaccine is ready for use; we are now awaiting official authorization,” she said.

Skvortsova said tests showed the vaccine to be safe even after repeated doses, while also producing strong results. Tumor shrinkage and slower progression were recorded in 60–80 percent of cases, depending on the cancer type, along with improved survival rates.

She added that the vaccine’s first application will target colorectal cancer, while advanced research is ongoing for vaccines against glioblastoma and certain melanomas, including ocular melanoma.

The announcement came during the 10th Eastern Economic Forum in Vladivostok, held from September 3 to 6, which drew more than 8,400 participants from over 75 countries.

Currently, cancer vaccines are available for some prostate and bladder cancers, with further research ongoing globally, according to the American Cancer Society.